ES2170798T3 - Benzopiranos y su uso como agentes terapeuticos. - Google Patents

Benzopiranos y su uso como agentes terapeuticos.

Info

Publication number
ES2170798T3
ES2170798T3 ES95921798T ES95921798T ES2170798T3 ES 2170798 T3 ES2170798 T3 ES 2170798T3 ES 95921798 T ES95921798 T ES 95921798T ES 95921798 T ES95921798 T ES 95921798T ES 2170798 T3 ES2170798 T3 ES 2170798T3
Authority
ES
Spain
Prior art keywords
benzopiranos
therapeutic agents
certain
transbenzopiranos
benzamids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95921798T
Other languages
English (en)
Inventor
Wai Ngor Chan
Helen Kate Ann Morgan
Mervyn Thompson
John Morris Evans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9411632A external-priority patent/GB9411632D0/en
Priority claimed from GB9411798A external-priority patent/GB9411798D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Application granted granted Critical
Publication of ES2170798T3 publication Critical patent/ES2170798T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

LA INVENCION SE RELACIONA CON CIERTOS CIS-BENZOPIRANOS Y TRANSBENZOPIRANOS, QUE PRESENTAN BENZAMIDAS SUSTITUIDAS EN POSICION C-4 Y CON SU USO EN EL TRATAMIENTO Y/O PREVENCION DE CIERTAS ALTERACIONES DEL SISTEMA NERVIOSO CENTRAL.
ES95921798T 1994-06-10 1995-05-31 Benzopiranos y su uso como agentes terapeuticos. Expired - Lifetime ES2170798T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9411632A GB9411632D0 (en) 1994-06-10 1994-06-10 Novel treatment
GB9411798A GB9411798D0 (en) 1994-06-13 1994-06-13 Novel treatment

Publications (1)

Publication Number Publication Date
ES2170798T3 true ES2170798T3 (es) 2002-08-16

Family

ID=26305044

Family Applications (2)

Application Number Title Priority Date Filing Date
ES01200801T Expired - Lifetime ES2207590T3 (es) 1994-06-10 1995-05-31 Benzopiranos y su uso como agentes terapeuticos.
ES95921798T Expired - Lifetime ES2170798T3 (es) 1994-06-10 1995-05-31 Benzopiranos y su uso como agentes terapeuticos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES01200801T Expired - Lifetime ES2207590T3 (es) 1994-06-10 1995-05-31 Benzopiranos y su uso como agentes terapeuticos.

Country Status (29)

Country Link
US (1) US5760074A (es)
EP (2) EP1114821B1 (es)
JP (2) JP3575767B2 (es)
KR (1) KR100397721B1 (es)
CN (2) CN1174975C (es)
AP (1) AP714A (es)
AT (2) ATE250052T1 (es)
AU (1) AU701060B2 (es)
BG (1) BG63339B1 (es)
BR (1) BR9507980A (es)
CA (1) CA2192480C (es)
CY (1) CY2508B1 (es)
CZ (1) CZ286081B6 (es)
DE (2) DE69524871T2 (es)
DK (2) DK0764157T3 (es)
ES (2) ES2207590T3 (es)
FI (1) FI120686B (es)
HK (1) HK1039115B (es)
HU (1) HUT76136A (es)
NO (1) NO315651B1 (es)
NZ (1) NZ287872A (es)
OA (1) OA10593A (es)
PL (1) PL188134B1 (es)
PT (2) PT1114821E (es)
RO (1) RO113463B1 (es)
SG (1) SG67930A1 (es)
SI (2) SI0764157T1 (es)
SK (1) SK281456B6 (es)
WO (1) WO1995034545A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010021780A1 (en) * 1992-12-11 2001-09-13 Smithkline Beecham P.L.C. Pharmaceutical composition containing bicyclic type compounds
GB9411635D0 (en) * 1994-06-10 1994-08-03 Smithkline Beecham Plc Novel treatment
US6492415B2 (en) * 1996-09-18 2002-12-10 Smithkline Beecham P.L.C. Use of benzopyranols to treat neurological disorders
GB9619492D0 (en) * 1996-09-18 1996-10-30 Smithkline Beecham Plc Novel treatment
GB9726543D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel compositions
GB9813949D0 (en) * 1998-06-29 1998-08-26 Smithkline Beecham Plc Novel compounds
GB0028697D0 (en) * 2000-11-23 2001-01-10 S P A Novel process
CA2602267A1 (en) * 2005-04-04 2006-10-12 Takeda Pharmaceutical Company Limited Use of ramelteon to treat and prevent depression and anxiety disorders
WO2009147441A2 (en) * 2008-06-05 2009-12-10 Minster Research Limited Novel treatments
CA2726878A1 (en) * 2008-06-05 2009-12-10 Minster Research Limited Novel treatments
WO2011067607A1 (en) 2009-12-03 2011-06-09 Minster Research Ltd Treatment of infectious diseases
EP2506846A1 (en) 2009-12-03 2012-10-10 Proximagen Limited Treatment of allodynia and hyperalgesia
US9499510B2 (en) 2012-07-03 2016-11-22 Proximagen Limited Pro-drug compounds
GB201304814D0 (en) * 2013-03-15 2013-05-01 Proximagen Ltd Pro-drug compounds
GB201322934D0 (en) 2013-12-23 2014-02-12 Proximagen Ltd Prodrug compounds
GB201322932D0 (en) * 2013-12-23 2014-02-12 Proximagen Ltd Pro-drug compounds
US12667586B2 (en) 2023-03-07 2026-06-30 Glaukos Corporation Treatments for ocular surface disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0126311B1 (en) * 1983-05-18 1989-09-13 Beecham Group Plc Benzopyran derivatives.
GB9112721D0 (en) * 1991-06-13 1991-07-31 Smithkline Beecham Plc Novel treatment
DE69327965T2 (de) * 1992-12-11 2000-10-19 Smithkline Beecham Corp., Philadelphia Pharmazeutische zusammenstellung enthaltende bizyklisch typ verbindungen
KR100326968B1 (ko) * 1992-12-11 2002-07-27 스미스클라인비이참피이엘시이 약학적 활성을 가진 이환식 화합물
US5536718A (en) * 1995-01-17 1996-07-16 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists

Also Published As

Publication number Publication date
HUT76136A (en) 1997-06-30
BG101040A (en) 1997-08-29
DE69531801T2 (de) 2004-07-01
AP9600889A0 (en) 1997-01-31
JP2003238554A (ja) 2003-08-27
HU9603415D0 (en) 1997-02-28
DK1114821T3 (da) 2004-02-02
SI0764157T1 (en) 2002-06-30
DK0764157T3 (da) 2002-04-22
WO1995034545A1 (en) 1995-12-21
OA10593A (en) 2002-07-10
ATE250052T1 (de) 2003-10-15
NO315651B1 (no) 2003-10-06
ES2207590T3 (es) 2004-06-01
BG63339B1 (bg) 2001-10-31
CA2192480C (en) 2007-07-24
FI120686B (fi) 2010-01-29
CN1336369A (zh) 2002-02-20
AU2672795A (en) 1996-01-05
ATE211469T1 (de) 2002-01-15
BR9507980A (pt) 1997-08-12
EP1114821A1 (en) 2001-07-11
HK1039115B (en) 2004-08-13
RO113463B1 (ro) 1998-07-30
SK281456B6 (sk) 2001-03-12
CA2192480A1 (en) 1995-12-21
PL317579A1 (en) 1997-04-14
EP1114821B1 (en) 2003-09-17
NO965260D0 (no) 1996-12-09
EP0764157B1 (en) 2002-01-02
HK1039115A1 (en) 2002-04-12
JPH10501251A (ja) 1998-02-03
DE69524871T2 (de) 2002-08-22
KR100397721B1 (ko) 2004-04-28
NO965260L (no) 1997-02-06
AP714A (en) 1998-12-23
CN1174975C (zh) 2004-11-10
US5760074A (en) 1998-06-02
PL188134B1 (pl) 2004-12-31
PT1114821E (pt) 2004-02-27
JP3575767B2 (ja) 2004-10-13
EP0764157A1 (en) 1997-03-26
FI964936L (fi) 1997-02-06
CN1234702C (zh) 2006-01-04
SK158796A3 (en) 1997-07-09
SG67930A1 (en) 1999-10-19
DE69531801D1 (de) 2003-10-23
CY2508B1 (en) 2005-12-23
CN1154698A (zh) 1997-07-16
AU701060B2 (en) 1999-01-21
NZ287872A (en) 1998-05-27
PT764157E (pt) 2002-06-28
FI964936A0 (fi) 1996-12-10
CZ286081B6 (cs) 2000-01-12
SI1114821T1 (en) 2004-02-29
HK1001286A1 (en) 1998-06-12
CZ361796A3 (en) 1997-08-13
DE69524871D1 (de) 2002-02-07

Similar Documents

Publication Publication Date Title
ES2127946T3 (es) Antagonistas de neurocinina diazabiciclica.
ES2176354T3 (es) Uso de nebivolol como agente anti-aterogenico.
MX9301634A (es) Quinuclidinas peptidicas.
ES2136723T3 (es) Utilizacion de n-aril-metilen-etilen-diamino-triacetatos, n-aril-metilen-imino-diacetatos o n,n'-diaril-metilen-etilen-diamino-acetatos contra el estres oxidante.
ES2071484T3 (es) Derivados de 2,4-diaminoquinazolinas para aumentar la actividad antitumoral.
ES2074867T3 (es) Derivados de quinazolina para potenciar la actividad antitumoral.
ES2157601T3 (es) Uso de agentes anti-microtubulos para tratar o prevenir la esclerosis multiple.
UY24799A1 (es) Derivados de 6-fenilpiridil-2-amina
ES2163090T3 (es) Uso de toxina botulinica para tratar la cefalea tensional.
DE69510940D1 (de) Pyrazolo und pyrrolopyridine
ES2179096T3 (es) Utilizacion de la interleucina-12 para prevenir la reaccion del injerto contra el huesped.
ES2184106T3 (es) Utilizacion del derivado de k-252a en el tratamiento de trastornos del sistema nervioso periferico o central, y de la hiperproduccion de citoquinas.
EA199900553A1 (ru) Чрескожная терапевтическая система
ES2132105T3 (es) 2-aminometil-cromanos como principios activos en farmacos para el tratamiento de enfermedades del sistema nervioso central.
MX9305269A (es) Utilizacion del receptor de il-4 para la terapia,la profilaxis y el diagnostico de enfermedades alergicas, viricas, parasitarias y bacterianas asi como de infecciones por hongos.
ATE232396T1 (de) Oxydiertes thymosin beta 4
GT199900214A (es) Combinacion de cerivastatina y fibratos.
PA8446301A1 (es) 2-amino-6-(4-fenoxi-2-sustituido)-piridinas sustituidas
ATE203519T1 (de) Chinolinderivate als antimalariamittel
PA8457001A1 (es) Derivados del 2-(4-aril o heteroaril-piperazin-i-ilmetil)-1h-indol
BG101040A (en) Benzopyrans and their use as therapeutic agents
TR199802504T2 (xx) N�rotoksik yaralanmalar�n tedavisi i�in bukminsterflirin kullan�lmas�.
ES2173180T3 (es) Derivados del mercaptoacetilamida hipocolesterolemicos, antiateroescleroticos e hipotrigliceridemicos.
ES2076141T3 (es) 5-aril-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
ES2125309T3 (es) Derivados de tiomarinol y procedimientos para su preparacion.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 764157

Country of ref document: ES